Rosuvastatin ön tedavisi koroner arter baypas greftleme sonrasında mikroalbuminüriyi azaltmaz
Yükleniyor...
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Öz: Amaç: Bu çalışmada rosuvastatinin, kardiyopulmoner baypas (KPB) eşliğinde yapılan koroner arter baypas greftleme (KABG) sonrasında mikroalbuminüriyi azaltıp azaltmadığı araştırıldı.Çalışma planı: Bu prospektif çalışmaya izole KABG yapılan toplam 40 hasta (37 erkek, 3 kadın; ort. yaş 59.0±10.1 yıl; dağılım 48-78 yıl) alındı. Hastalar kontrol grubu (n=20) ve elektif KABG'den yedi gün önce 20 mg/gün rosuvastatin kullanmış hastalardan oluşan rosuvastatin grubu (n=20) olarak ikiye ayrıldı. Tüm hastalardan mikroalbuminüri idrar sondası takıldığında, KPB'nin başlangıcından önce, KPB'nin sonlandırıldığı anda ve yoğun bakım ünitesinde altıncı ve 24. saatlerde spot idrar örneği ile ölçüldü. Serum C-reaktif protein ise anestezi indüksiyonundan önce ve yoğun bakım ünitesinde altıncı ve 24. saatte kan örneği ile ölçüldü.Bul gu lar: Hastaların demografik verileri ve ameliyat öncesi özellikleri benzerdi. Gruplar arasında KPB, kros klemp ve ameliyat süreleri, inotrop desteği, ekstübasyon süreleri ve hastaneden taburculuk süreleri arasında anlamlı fark bulunmadı. Üriner albümin/kreatinin oranları her iki grupta başlangıç ölçümüne kıyasla artmıştı ve KPB sonunda maksimum düzeye ulaştı (p<0.05). Yoğun bakımda altıncı saatte ölçülen albümin/kreatinin oranı, rosuvastatin grubunda anlamlı düzeyde yüksekti (0.69'a kıyasla 2.10, p=0.002). Serum C-reaktif protein her iki grupta da cerrahi sonrası 24. saatte artış gösterdi.So nuç: Rosuvastatin ön tedavisi, KABG sonrasında mikroalbüminüriyi ve inflamatuvar yanıtı azaltmaz.
Abstract: Background: This study aims to evaluate whether rosuvastatin attenuates microalbuminuria following coronary artery bypass grafting (CABG) with a cardiopulmonary bypass (CPB). Methods: This prospective study was performed in 40 patients (37 males, 3 females; mean age 59.0±10.1 years; range 48 to 78 years) who were scheduled for isolated CABG. The patients were divided into two groups including control group (n=20) and rosuvastatin group (n=20) which received rosuvastatin 20 mg/day seven day (20 mg/day) before elective CABG. Microalbuminuria was measured after the insertion of the urinary catheter, before CPB, after the termination of CPB, and at the sixth and 24th hours in the intensive care unit using a spot urine sample. Serum C-reactive protein was measured before the induction of anesthesia and at the sixth and 24th hours in the intensive care unit using blood samples. Results: The demographic data and preoperative characteristics of the patients were similar. There were no significant differences in the CPB, cross-clamp and surgery time, inotropic support, extubation times, and time to discharge from hospital between the two groups. The urinary albumin/creatinine ratio increased in both groups, compared to the baseline measurement and reached a maximum level at the end of CPB (p<0.05). Albumin/ creatinine ratio measured at the sixth hour in the intensive care unit was significantly higher in the rosuvastatin group (0.69 vs. 2.10, p=0.002). Serum C-reactive protein increased at 24 hour postoperatively in both groups. Conclusion: Rosuvastatin pretreatment does not attenuate microalbuminuria and the inflammatory response after CABG surgery.
Abstract: Background: This study aims to evaluate whether rosuvastatin attenuates microalbuminuria following coronary artery bypass grafting (CABG) with a cardiopulmonary bypass (CPB). Methods: This prospective study was performed in 40 patients (37 males, 3 females; mean age 59.0±10.1 years; range 48 to 78 years) who were scheduled for isolated CABG. The patients were divided into two groups including control group (n=20) and rosuvastatin group (n=20) which received rosuvastatin 20 mg/day seven day (20 mg/day) before elective CABG. Microalbuminuria was measured after the insertion of the urinary catheter, before CPB, after the termination of CPB, and at the sixth and 24th hours in the intensive care unit using a spot urine sample. Serum C-reactive protein was measured before the induction of anesthesia and at the sixth and 24th hours in the intensive care unit using blood samples. Results: The demographic data and preoperative characteristics of the patients were similar. There were no significant differences in the CPB, cross-clamp and surgery time, inotropic support, extubation times, and time to discharge from hospital between the two groups. The urinary albumin/creatinine ratio increased in both groups, compared to the baseline measurement and reached a maximum level at the end of CPB (p<0.05). Albumin/ creatinine ratio measured at the sixth hour in the intensive care unit was significantly higher in the rosuvastatin group (0.69 vs. 2.10, p=0.002). Serum C-reactive protein increased at 24 hour postoperatively in both groups. Conclusion: Rosuvastatin pretreatment does not attenuate microalbuminuria and the inflammatory response after CABG surgery.
Açıklama
Anahtar Kelimeler
Kaynak
Türk Göğüs Kalp Damar Cerrahisi Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
22
Sayı
3
Künye
SEÇİCİ S,BATTALOĞLU B,UYAR İ. S,AKPINAR M. B,ABACILAR A. F,DİŞLİ O. M,ERDİL N,TAŞKAPAN M. Ç (2014). Rosuvastatin ön tedavisi koroner arter baypas greftleme sonrasında mikroalbuminüriyi azaltmaz. Türk Göğüs Kalp Damar Cerrahisi Dergisi, 22(3), 496 - 501.
